Contributions to Science:
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Blum K, Modestino EJ, Neary J, Gondré-Lewis MC, Siwicki D, Moran M, Hauser M, Braverman ER, Baron D, Steinberg B, Laughlin TM, Badgaiyan RD; Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4.
Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic.
Blum K, Jacobs W, Modestino EJ, DiNubile N, Baron D, McLaughlin T, Siwicki D, Elman I, Moran M, Braverman ER, Thanos PK, Badgaiyan RD; SEJ Surg Pain. 2018 Oct 4;1(1):1-11.
Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.
Raymond Brewer, Kenneth Blum*, Abdalla Bowirrat, Edward J. Modestino, David Baron, Rajendra D. Badgaiyan, Mark Moran, Brent Boyett and Mark S. Gold, Current Psychopharmacology (2020) 9: 1. https://doi.org/10.2174/2211556009999200628093231
High genetic addiction risk score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: an open clinical pilot trial.
Mark Moran, 1,2 Kenneth Blum*,2-10 Jessica Valdez Ponce,2 Lisa Lott,2 Marjorie C. Gondré – Lewis,11 Sampada Badgaiyan,2 Raymond Brewer,2,8 B. William Downs,9 Philip Fynman,12 Alexander Weingarten,12,13 Jean Lud Cadet14, David E. Smith,15 David Baron,5 Panayotis K (submitted to Molecular Neurobiology)
Epigenetic trait evidence for hyperdopaminergic (surfeit) during brain development and genetic state evidence for hypodopaminergia (deficit) in adolescents: nutrigenomic solutions
Kenneth Blum, Bruce Steinberg, Lisa Lott, Jessica Valdez Ponce, Mark Moran, B.W Down, Edward J Modestino, Panayotis K Thanos , Thomas McLaughlin, Marjorie C. Gondre Lewis, David Baron, David Siwicki, Joseph Morgan, Margaret A. Madigan, Raju Hajela, Igor Elman, Debra Barh, Brent Boyett, Arwen Podesta, A. Kenison Roy, Sampoda Badgaiyan, Thomas A. Simpatico, Mary Hauser, Rajendra D. Badgaiyan; (submitted to Current Psychopharmacology)
Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action.
Kenneth Blum*, Todd C. Pappas, Bryan Clifton, David Baron, Margaret A. Madigan, Lisa Lott, Mark Moran, Cannon Clifton, Scott Worrich, Ervey Clarke, Brent Boyett, Abdalla Bowirrat and Mark S. Gold Current Psychopharmacology; 99 – 112 ( 14 ); [ Vol. 8 , Issue. 2 ].
Precision Behavioral Management (PBM) a Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS)
K. Blum, A K. Roy III, A. Podesta, E.J., Modestino, B. Steinberg, M.C. Gondré -Lewis, D. Baron, P.K, Thanos, L.Lott, J. ValdezPonc, B. Boyett, D. Siwicki, M. Moran, I. Elman, D. Edwards, T. McLaughlin, E.R. Braverman, T. Simpatico, M. Hauser, B.W. Downs, R.D. Badgaiyan Book Chapter-Cambridge Handbook on SUD and Behavioral Addictions.2020 page 297 Chapter 24
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
Kenneth Blum, Edward J Modestino, Jennifer Neary, Marjorie C Gondré-Lewis, David Siwicki, Mark Moran, Mary Hauser, Eric R Braverman, David Baron, Bruce Steinberg, Thomas Mc Laughlin, Rajendra D Badgaiyan; Biomed J Sci Tech Res. 2018 Jan 7; 2(2): 1–4.
Previous Research Experience
2007-2008:
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group With A Crossover
Confirmation Period Study Of “Study Drug” For The Treatment Of Postherpetic Neuralgia
2007-2008:
A Randomized, Double-Blind, Active-Controlled Crossover Study To Evaluate The Efficacy And Safety Of “Study Drug” Compared With “Study Drug” For The Management Of Breakthrough Pain In Opioid-Tolerant Patients With Chronic Pain
2007-2008:
Randomized, Double-Blind, Placebo-Controlled Multi-Center Study To Evaluate The Safety
And Efficacy Of “Study Drug” For The Treatment Of Breakthrough Cancer Pain.
